Softwr

Healthcare · head to head

Signant Health vs Woebot Health

Signant Health logo

Signant Health

Healthcare

eCOA-first clinical trial platform that has grown outward into EDC, eConsent and televisits

From
On request
Rated
-
Full reviewWebsite
Woebot Health logo

Woebot Health

Healthcare

Conversational CBT chatbot that withdrew from consumer distribution and now sells only to payers and providers

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Signant Health no pricing is published, and the software licence is a minority of the real bill once instrument licensing, translations, device provisioning and services are added, so early budget estimates are routinely too low.; Woebot Health the company withdrew its consumer app in June 2025 after concluding FDA marketing authorisation was not achievable at acceptable cost, which is a plain signal about both regulatory position and commercial durability.
  • They diverge on capability: Signant Health covers eCOA and ePRO, Woebot Health covers Scripted CBT dialogue.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Signant Health and Woebot Health actually diverge.

Attributes where Signant Health and Woebot Health differ
AttributeSignant HealthWoebot Health
PlatformsWeb, iOS, AndroidiOS, Android, Web

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Signant Health

  • eCOA and ePRO
  • Unified platform
  • eConsent
  • Randomisation and supplies
  • TeleVisits
  • Rater training
  • Data surveillance
  • Instrument library

Only in Woebot Health

  • Scripted CBT dialogue
  • Mood tracking
  • Crisis routing
  • Between-session support
  • Payer deployment
  • Provider copilot positioning
  • Research licensing
  • Population reporting

What people use each for

The jobs each tool is most often brought in to do.

Signant Health

  • A central nervous system or psychiatry trial where the primary endpoint is a rated scale and rater consistency decides the readoutnot Woebot Health
  • A global study needing an outcome instrument translated and linguistically validated across a dozen languagesnot Woebot Health
  • A decentralised or hybrid protocol combining televisits, eConsent and at-home patient reported outcomesnot Woebot Health
  • A sponsor consolidating separate eCOA, eConsent and randomisation vendors onto one platform to cut reconciliation worknot Woebot Health

Woebot Health

  • A health plan wanting a low intensity behavioural health option for members on a waiting list for therapynot Signant Health
  • A provider organisation offering structured between-session CBT practice to patients already in treatmentnot Signant Health
  • A research group running a trial that needs a clinically scripted rather than generative conversational agent for safety reasonsnot Signant Health
  • A payer targeting a specific population such as postpartum members where scripted CBT content already existsnot Signant Health

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Signant Health

  • No pricing is published, and the software licence is a minority of the real bill once instrument licensing, translations, device provisioning and services are added, so early budget estimates are routinely too low.
  • Linguistic validation is charged per instrument per language and is on the critical path to first patient in, so adding a country late in start-up produces both a cost and a schedule hit.
  • Provisioned participant devices bring logistics, replacement, shipping and cellular connectivity obligations that persist for the life of the trial and are frequently underestimated.
  • The EDC component is newer than the eCOA heritage, so sponsors with complex data management requirements often keep an incumbent EDC and lose the single-database benefit that justifies the platform.
  • It is priced and scoped for sponsor-grade trials, which makes it a poor fit for investigator-initiated or academic studies that need outcome collection without the services layer.

Woebot Health

  • The company withdrew its consumer app in June 2025 after concluding FDA marketing authorisation was not achievable at acceptable cost, which is a plain signal about both regulatory position and commercial durability.
  • It is not an FDA cleared treatment for any indication, so it cannot be positioned to members as therapy and cannot substitute for a covered behavioural health benefit.
  • The scripted, non-generative design that makes it safe also makes it feel rigid next to current conversational AI, and engagement drops off quickly once users hit the edges of the script.
  • Published evidence is short-horizon symptom change in selected populations, mostly young adults, with little evidence of durable benefit or effect at whole-population scale.
  • With consumer distribution gone, the remaining business depends on a small number of payer and provider contracts, so a buyer should assume real vendor continuity risk over a multi-year term.

Pricing, plan by plan

Signant Health

On request
  • SmartSignals Unified Platform$undefined/year
    • Priced per study through a sales process
    • Modules selected per protocol: EDC, eCOA, randomisation, eConsent, TeleVisits
    • Instrument licensing paid to scale owners on top of platform cost

Woebot Health

On request
  • Woebot for payers and providers$undefined/year
    • Contracted per member per month or as a population licence
    • Sold to health plans and provider organisations, not to employers or individuals
    • No consumer purchase route since the app closed in June 2025

Which should you pick?

Choose Signant Health if

  • You need ecoa and epro.
  • You work on Web, iOS, Android.
  • You also want unified platform.
Signant Health review

Choose Woebot Health if

  • You need scripted cbt dialogue.
  • You work on iOS, Android, Web.
  • You also want mood tracking.
Woebot Health review

Questions people ask

Is Signant Health or Woebot Health better?
Neither clearly leads. Signant Health starts at On request and Woebot Health at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Signant Health or Woebot Health?
Signant Health starts at On request and Woebot Health at On request.
Does Signant Health or Woebot Health run on more platforms?
Signant Health runs on Web, iOS, Android. Woebot Health runs on iOS, Android, Web.
What is Signant Health best used for?
Signant Health is most often used for a central nervous system or psychiatry trial where the primary endpoint is a rated scale and rater consistency decides the readout, a global study needing an outcome instrument translated and linguistically validated across a dozen languages, a decentralised or hybrid protocol combining televisits, econsent and at-home patient reported outcomes, a sponsor consolidating separate ecoa, econsent and randomisation vendors onto one platform to cut reconciliation work. Of those, a central nervous system or psychiatry trial where the primary endpoint is a rated scale and rater consistency decides the readout and a global study needing an outcome instrument translated and linguistically validated across a dozen languages are not what Woebot Health is typically brought in for.
What can Signant Health do that Woebot Health cannot?
Signant Health covers eCOA and ePRO, Unified platform, eConsent, Randomisation and supplies. Woebot Health covers Scripted CBT dialogue, Mood tracking, Crisis routing, Between-session support.

Answered from the vendors’ own pages

Signant Health: What is Signant best at?

Electronic clinical outcome assessment, particularly rated scales in central nervous system and psychiatry trials, together with rater training and endpoint quality services.

Woebot Health: Is Woebot still available?

Not to consumers. The consumer app closed in June 2025. The company continues to offer the product to payers, providers and researchers.

Signant Health: Is pricing published?

No. Everything is quoted per study, and instrument licences, translations and devices sit on top of the platform cost.

Woebot Health: Is it FDA cleared?

No. It held Breakthrough Device designation but never obtained marketing authorisation, and the founder cited the cost of that pathway as the reason for closing the consumer app.

Signant Health: Can I use it only for eCOA?

Yes. The modules are selected per protocol, and many sponsors take eCOA and eConsent while keeping an existing EDC.

Woebot Health: Is it generative AI?

Historically no. The dialogue is clinician-written and rule-based, a deliberate safety choice that limits how naturally it converses.

Signant Health: What drives the timeline?

Translation and linguistic validation of outcome instruments, which is per language per instrument and sits on the critical path to study start.

Woebot Health: What does the evidence show?

Randomised studies reported reduced depressive symptoms over short periods in selected populations, notably young adults. That is symptom change in a trial, not demonstrated population outcomes.

Share

Related pages

More on Signant Health

More on Woebot Health

Keep looking

Other head to heads